News

Devdiscourse12h
Merck's Bold $3.9 Billion Bid on SpringWorks: A Game-Changer in Rare Cancer Therapies
Germany’s Merck KGaA has agreed to acquire U.S. biotech SpringWorks Therapeutics for $3.9 billion. The acquisition, aimed at ...
SpringWorks: Acquired By Merck KGaA Based On Rare Tumor Targeting Drugs Like OGSIVEO
Merck KGaA acquires SpringWorks Therapeutics, Inc. for $3.9B, boosting its pipeline with OGSIVEO & GOMEKLI. Click for more on ...
Fierce Pharma1d
Merck KGaA springs back into M&A game with $3.9B buyout of Pfizer spinout SpringWorks
Merck KGaA’s long courtship of SpringWorks Therapeutics has come to fruition as the German drugmaker has bought out the ...
GEN - Genetic Engineering and Biotechnology News16h
Merck KGaA to Acquire SpringWorks for $3.9B, Expanding Rare Cancer Footprint
Merck KGaA said the deal will grow its U.S. presence and expand the reach of SpringWorks’ drugs, including one approved in February.
Stamford-based drug developer for rare cancers and tumors sold for $3.9 billion to German company
After developing treatments for rare tumors, SpringWorks Therapeutics is taking a buyout offer from Germany-based Merck KGaA.
Devdiscourse3d
Global Health Updates: From Mergers to Measles and Medicine
The latest health-related developments include Merck's acquisition talks with SpringWorks, disbandment of a US Justice ...